How to follow-up a patient who received tocilizumab in severe COVID-19: a case report

BACKGROUND: COVID-19 is characterized by fast deterioration in the mechanism of cytokine storm. Therefore, treatment with immunomodulating agents should be initiated as soon as hyperinflammation is established. Evidence for the use of tocilizumab (TCZ) in COVID-19 is emerging, but the drug in this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Podlasin, Regina B., Kowalska, Justyna D., Pihowicz, Andrzej, Wojtycha-Kwaśnica, Beata, Thompson, Magdalena, Dyda, Tomasz, Czeszko-Paprocka, Hanna, Horban, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450912/
https://www.ncbi.nlm.nih.gov/pubmed/32854774
http://dx.doi.org/10.1186/s40001-020-00438-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450912/
https://www.ncbi.nlm.nih.gov/pubmed/32854774
http://dx.doi.org/10.1186/s40001-020-00438-x

Ejemplares similares